Table 1.
Study, Year [Ref.] | Study Design | N° of Patients | Population | Control Group | MMP | Other Factos | Outcomes | Main Findings |
---|---|---|---|---|---|---|---|---|
Bradham, 2002 [10] | Prospective observational NRCT | 51 | Patient with HOCM submitted to alcohol septal ablation (51 pts) | - | MMP-2, MMP-8, MMP-9, MMP-13, TIMP-1 | CK CK-MB1 |
|
|
Lombardi, 2003 [11] | Prospective observational NRCT | 50 | Patient with HOCM (36 pts) | Healthy subjects (14 pts) | MMP-1, MMP-2, MMP-9, TIMP-1 | ICTP, PICP, PINP |
|
|
Fassbach, 2004 [12] | Prospective observational NRCT | 64 | Patient with HOCM (26 pts) | Healthy subjects (38 pts) | MMP-1, TIMP-1 | ICTP, PICP |
|
|
Noji, 2004 [13] | Prospective observational NRCT | 78 | Patient with HOCM (28 pts) | Healthy subjects (50 pts) | MMP-2, MMP-3, MMP-9, TIMP-1, TIMP-2 |
- |
|
|
Stroud, 2005 [14] | Prospective observational NRCT | 34 | Patient with HOCM submitted to alcohol septal ablation (18 pts) | Healthy subjects (16 pts) | TIMP-4 | - |
|
|
Roldàn, 2008 [15] | Prospective observational NRCT | 125 | Patient with HOCM (67 pts) | Healthy subjects (58 pts) | MMP-1, MMP-2, MMP-9, TIMP-1 | NT-proBNP |
|
|
Saura, 2009 [16] | Prospective observational NRCT | 73 | Patient with HOCM (73 pts) | - | MMP-2, TIMP-1 | NT-pro-BNP, C-reactive protein |
|
|
Kitaoka, 2010 [17] | Retrospective observational NRCT | 41 | Patient with HOCM (41 pts) | - | MMP-2, MMP-9, TIMP-1 |
BNP |
|
|
Kitaoka, 2011 [18] | Prospective observational NRCT | 16 * | Patient with HOCM (16 pts) | - | MMP-2, MMP-9, TIMP-1 |
BNP |
|
|
Zachariah, 2012 [19] | Prospective observational NRCT | 45 | Patient with HOCM (45 pts) | - | MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1, TIMP-2, TIMP-3, TIMP-4 | - |
|
|
Fucikova, 2016 [20] | Prospective observational NRCT | 30 | Patient with HOCM (17 pts) | Healthy subjects (17 pts) | MMP-2, MMP-9, TIMP-1, TIMP-2 | BNP, fibronectin |
|
|
Munch, 2016 [21] | Retrospective observational NRCT | 54 | Patient with HOCM (54 pts) | - | MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1 | - |
|
|
Fernlund, 2017 [22] | Prospective observational NRCT | 105 | Patient with HOCM (39 pts) | Healthy subjects (66 pts) | MMP-9 | - |
|
|
Yang, 2019 [23] | Prospective observational NRCT | 52 | Patient with HOCM submitted to surgical myectomy (52 pts) | - | MMP-2, MMP-9, TIMP-1 | - |
|
|
Qian, 2020 [24] | Prospective observational NRCT | 30 | Patient with HOCM submitted to percutaneous intramyocardial septal radiofrequency ablation (30 pts) | - | MMP-2 | - |
|
|
Bi, 2021 [25] | Prospective observational NRCT | 55 | Patient with HOCM submitted to surgical myectomy (55 pts) | - | MMP-2, MMP-9, TIMP-1 | - |
|
|
* Among 16 patients, 11 patients were included in a previous study by the same group (Kitaoka 2010). Abbreviations: CK, creatine kinase; EF, ejection fraction; HOCM, hypertrophic obstructive cardiomyopathy; ICTP, collagen I carboxy-terminal telopeptide; LV, left ventricle; MI, myocardial infarction; MMP, metalloproteinase; NRCT, not randomized controlled trial; NT-proBNP, N-terminal pro B-type natriuretic peptide; PICP, procollagen type I carboxy-terminal propeptide; PINP, procollagen type I amino-terminal propeptide; RCT, randomized controlled trial; TIMP, tissue inhibitors of metalloproteinases.